Prospective phase II trial of fulvestrant in the treatment of recurrent ovarian carcinoma

被引：0
|
作者：
Thomas, S. G. [1 ]
Judson, P. L. [1 ]
Carson, L. F. [1 ]
Downs, L. S. [1 ]
Ghebre, R. [1 ]
Geller, M. A. [1 ]
Jonson, A. L. [1 ]
Argenta, P. A. [1 ]
机构：
[1] Univ Minnesota, Minneapolis, MN USA
来源：
GYNECOLOGIC ONCOLOGY | 2009年 / 112卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
58
引用
收藏
页码：S32 / S32
页数：1
相关论文
共 50 条
  • [1] Phase II trial of fulvestrant in the treatment of recurrent ovarian carcinoma
    Thomas, S. G.
    Judson, P. L.
    Carson, L. F.
    Downs, L. S., Jr.
    Gliebre, R. G.
    Geller, M. A.
    Jonson, A. L.
    Argenta, P. A.
    GYNECOLOGIC ONCOLOGY, 2008, 111 (02) : 374 - 375
  • [2] A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer
    Argenta, Peter A.
    Thomas, Sajeena G.
    Judson, Patricia L.
    Downs, Levi S., Jr.
    Geller, Melissa A.
    Carson, Linda F.
    Jonson, Amy L.
    Ghebre, Rahel
    GYNECOLOGIC ONCOLOGY, 2009, 113 (02) : 205 - 209
  • [3] Phase II trial with Topotecan and Ifosfamide combination in the treatment of recurrent ovarian cancer
    Latorre, A.
    Decio, R.
    Calabrese, R.
    Giampaglia, M.
    Spada, M.
    Misino, A.
    Cova, D.
    Baruffi, S.
    Lombardi, F.
    Lorusso, V.
    ANNALS OF ONCOLOGY, 2005, 16 : 154 - 154
  • [4] PHASE II TRIAL WITH TOPOTECAN AND IFOSFAMIDE COMBINATION IN THE TREATMENT OF RECURRENT OVARIAN CANCER
    Latorre, A.
    Decio, R.
    Calabrese, R.
    Giampaglia, M.
    Spada, M.
    Lorusso, V.
    ANNALS OF ONCOLOGY, 2004, 15 : 93 - 93
  • [5] Surufatinib combined with toripalimab for the treatment of recurrent ovarian clear cell carcinoma: a prospective single center, single-arm phase II clinical trial
    Ye, Shuang
    Fu, Yi
    Liu, Shuai
    Wang, Jun
    Zhou, Lin
    Jiang, Wei
    Pei, Xuan
    Shen, Wenbin
    Sun, Min
    Shan, Boer
    Yang, Huijuan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A262 - A263
  • [6] A phase II trial of sunitinib in recurrent and refractory ovarian, fallopian tube, and peritoneal carcinoma
    Campos, S.
    Penson, R.
    Berlin, S.
    Matulonis, U.
    Horowitz, N.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S119 - S120
  • [7] A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma - A Gynecologic Oncology Group Study
    Look, KY
    Blessing, JA
    Adelson, MD
    Morris, M
    Bookman, MA
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (01): : 7 - 9
  • [8] Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma
    Hoffman, MA
    Blessing, JA
    Morgan, M
    GYNECOLOGIC ONCOLOGY, 2000, 79 (03) : 463 - 465
  • [9] A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma
    Campos, Susana M.
    Penson, Richard T.
    Matulonis, Ursula
    Horowitz, Neil S.
    Whalen, Christin
    Pereira, Lauren
    Tyburski, Karin
    Roche, Maria
    Szymonifka, Jackie
    Berlin, Suzanne
    GYNECOLOGIC ONCOLOGY, 2013, 128 (02) : 215 - 220
  • [10] Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: A phase II trial
    Shawky, Hanan
    Tawfik, Hesham
    Hewidy, Medhat
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2014, 26 (03) : 139 - 145
12345